Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00895739|
Recruitment Status : Unknown
Verified May 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : May 8, 2009
Last Update Posted : August 12, 2013
RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts. Giving alemtuzumab together with cyclosporine may be an effective treatment for severe aplastic anemia or acquired marrow failure.
PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with cyclosporine and to see how well it works in treating patients with severe aplastic anemia or acquired marrow failure.
|Condition or disease||Intervention/treatment||Phase|
|Nonmalignant Neoplasm||Biological: alemtuzumab Drug: cyclosporine||Phase 2|
- Determine the safety of alemtuzumab and low-dose cyclosporine, as defined by occurrence of adverse effects, in patients with severe aplastic anemia or single lineage acquired marrow failure.
- Determine the efficacy of this regimen, in terms of overall survival, hematological response (partial and complete response, including time to response) and failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse), in these patients.
- Evaluate the incidence of adverse effects after treatment.
- Evaluate the long-term safety of alemtuzumab treatment.
- Determine the time to achieve a complete hematological response.
- Determine the proportion of patients maintaining hematological response free of any treatment.
- Determine the incidence of relapse in responding patients.
- Determine the incidence of severe infections.
- Determine the requirement for IV antibiotics and antifungal therapy.
- Determine the requirement for red cell and platelet transfusion.
- Determine the incidence of CMV reactivation.
- Determine the kinetics of immune reconstitution.
- Determine the incidence of paroxysmal nocturnal hemoglobinuria clone (lymphoid or myeloid) development.
- Determine the incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia).
OUTLINE: Patients receive alemtuzumab subcutaneously on days 1-5*. Patients also receive oral cyclosporine beginning on day 7 and continuing for ≥ 180 days, followed by a taper according to clinical condition.
NOTE: *Patients with single lineage aquired marrow failure receive alemtuzumab on days 1-4.
After completion of study therapy, patients will be followed up every 3 months for up to 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Masking:||None (Open Label)|
|Official Title:||Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients|
|Study Start Date :||June 2006|
- Safety, as defined by occurrence of adverse effects
- Overall survival
- Hematologic response (partial and complete response, including time to response)
- Failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse)
- Incidence of adverse effects after treatment
- Long-term safety of alemtuzumab treatment
- Time to achieve a complete hematological response
- Proportion of patients maintaining hematological response free of any treatment
- Incidence of relapse in responding patients
- Incidence of severe infections
- Requirement for IV antibiotics and antifungal therapy
- Requirement for red cell and platelet transfusion
- Incidence of CMV reactivation
- Kinetics of immune reconstitution
- Incidence of paroxysmal nocturnal hemoglobinuria (PNH) clone (lymphoid or myeloid) development
- Incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00895739
|Federico II University Medical School||Recruiting|
|Naples, Italy, 80131|
|Contact: Bruno Rotoli, MD 39-081-746-2068 firstname.lastname@example.org|
|Principal Investigator:||Bruno Rotoli, MD||Federico II University|